Du är här

2017-05-22

AstraZeneca: AstraZeneca enters agreement with Recordati for Seloken in Europe

Agreement expands the commercial potential of Seloken in European
markets

AstraZeneca to receive upfront payment, plus ongoing income for
established heart medicines

AstraZeneca announced today that it has entered into an agreement with
Recordati S.p.A (Recordati) for the commercial rights to
Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate
respectively) and associated Logimax fixed-dose combination
(metoprolol succinate and felodipine) treatments in Europe.
Metoprolol succinate is a beta-blocker for the control of
hypertension, angina and heart failure.

Recordati will pay AstraZeneca $300 million upon completion of the
agreement. AstraZeneca will also receive sales-related income through
tiered royalties, initially at a double-digit percentage of sales.
AstraZeneca will manufacture and supply the medicines to Recordati
under a supply agreement.

Mark Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca, said: "This agreement allows us to
concentrate our resources on bringing multiple new medicines to
patients. Recordati's expertise in cardiovascular disease and
established European salesforce will help to expand the commercial
potential of the Seloken brands, which are mature medicines for the
new AstraZeneca."

Financial considerations

In 2016, Product Sales for the Seloken brands and Logimax were $110
million in Europe. AstraZeneca will continue to commercialise the
medicines in all other markets, where it holds the rights. The
transaction is expected to complete in the second quarter of 2017,
subject to customary closing conditions and regulatory clearances.
Based on the level of ongoing interest AstraZeneca will retain in the
brands in Europe, the $300 million upfront and tiered royalties will
be reported as Other Operating Income in the Company's financial
statements. The agreement does not impact the Company's financial
guidance for 2017.

- ENDS -

NOTES TO EDITORS

About Seloken

Seloken (metoprolol) is indicated for the control of a range of
conditions including hypertension, angina pectoris, disturbances of
cardiac rhythm, maintenance treatment after myocardial infarction and
functional heart disorders with palpitations. It is available in
European markets under brand names including Seloken, Seloken ZOK
(extended release), Selo-Sok and Betaloc ZOK. Logimax is the
fixed-dose combination of metoprolol succinate with felodipine. It is
indicated for the control of hypertension.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca
operates in over 100 countries and its innovative medicines are used
by millions of patients worldwide. For more information, please visit
www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677

Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-enters-agreement-wit...

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.